Cargando…

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms. The PCSK9 plasma levels change according to lipid lowering therapy (LLT). Few da...

Descripción completa

Detalles Bibliográficos
Autores principales: Toscano, Arianna, Cinquegrani, Maria, Scuruchi, Michele, Di Pino, Antonino, Piro, Salvatore, Ferrara, Viviana, Morace, Carmela, Lo Gullo, Alberto, Imbalzano, Egidio, Purrello, Francesco, Squadrito, Giovanni, Scicali, Roberto, Mandraffino, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033040/
https://www.ncbi.nlm.nih.gov/pubmed/35454151
http://dx.doi.org/10.3390/biom12040562
_version_ 1784692792981716992
author Toscano, Arianna
Cinquegrani, Maria
Scuruchi, Michele
Di Pino, Antonino
Piro, Salvatore
Ferrara, Viviana
Morace, Carmela
Lo Gullo, Alberto
Imbalzano, Egidio
Purrello, Francesco
Squadrito, Giovanni
Scicali, Roberto
Mandraffino, Giuseppe
author_facet Toscano, Arianna
Cinquegrani, Maria
Scuruchi, Michele
Di Pino, Antonino
Piro, Salvatore
Ferrara, Viviana
Morace, Carmela
Lo Gullo, Alberto
Imbalzano, Egidio
Purrello, Francesco
Squadrito, Giovanni
Scicali, Roberto
Mandraffino, Giuseppe
author_sort Toscano, Arianna
collection PubMed
description Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms. The PCSK9 plasma levels change according to lipid lowering therapy (LLT). Few data exist regarding the role of PCSK9 in vascular damage. We aimed to evaluate the impact of PCSK9 plasma levels on pulse wave velocity (PWV) and the effect of PCSK9 inhibitors (PCSK9-i) on circulating PCSK9 and PWV in a cohort of heterozygous familial hypercholesterolemia (HeFH) subjects. In a previous step, HeFH patients were enrolled and LLT was prescribed according to guidelines. Biochemical analyses and PWV assessment were performed at baseline (T0), after 6 months of high-efficacy statin plus ezetimibe (T1) and after 6 months of PCSK9-i (T2). The PCSK9 levels were evaluated in 26 selected HeFH subjects at the three time points and 26 healthy subjects served as controls for the reference value for PCSK9 plasma levels. The PWV values decreased at each time point in HeFH subjects after LLT starting (8.61 ± 2.4 m/s, −8.7%; p < 0.001 vs. baseline at T1, and 7.9 ± 2.1 m/s, −9.3%; p < 0.001 vs. both T1 and baseline) and it was correlated to PCSK9 (r = 0.411, p = 0.03). The PCSK9 levels increased on statin/EZE therapy (+42.8% at T1) while it decreased after PCSK9-i was started (−34.4% at T2). We noted a significant relationship between PCSK9 levels and PWV changes at T1 and T2. In conclusion, PCSK9 levels were associated with baseline PWV values in HeFH subjects; moreover, we found that PCSK9 level variations seemed to be correlated with PWV changes on LLT. A longer observation time and wider sample size are needed to assess the potential role of PCSK9 plasma levels on the vascular function and remodelling, and to clarify the effects of PCSK9-i in these pathways.
format Online
Article
Text
id pubmed-9033040
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90330402022-04-23 PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy Toscano, Arianna Cinquegrani, Maria Scuruchi, Michele Di Pino, Antonino Piro, Salvatore Ferrara, Viviana Morace, Carmela Lo Gullo, Alberto Imbalzano, Egidio Purrello, Francesco Squadrito, Giovanni Scicali, Roberto Mandraffino, Giuseppe Biomolecules Article Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a key regulator of low-density lipoprotein (LDL) metabolism involved in the degradation of the low-density lipoprotein receptor (LDLR) through complex mechanisms. The PCSK9 plasma levels change according to lipid lowering therapy (LLT). Few data exist regarding the role of PCSK9 in vascular damage. We aimed to evaluate the impact of PCSK9 plasma levels on pulse wave velocity (PWV) and the effect of PCSK9 inhibitors (PCSK9-i) on circulating PCSK9 and PWV in a cohort of heterozygous familial hypercholesterolemia (HeFH) subjects. In a previous step, HeFH patients were enrolled and LLT was prescribed according to guidelines. Biochemical analyses and PWV assessment were performed at baseline (T0), after 6 months of high-efficacy statin plus ezetimibe (T1) and after 6 months of PCSK9-i (T2). The PCSK9 levels were evaluated in 26 selected HeFH subjects at the three time points and 26 healthy subjects served as controls for the reference value for PCSK9 plasma levels. The PWV values decreased at each time point in HeFH subjects after LLT starting (8.61 ± 2.4 m/s, −8.7%; p < 0.001 vs. baseline at T1, and 7.9 ± 2.1 m/s, −9.3%; p < 0.001 vs. both T1 and baseline) and it was correlated to PCSK9 (r = 0.411, p = 0.03). The PCSK9 levels increased on statin/EZE therapy (+42.8% at T1) while it decreased after PCSK9-i was started (−34.4% at T2). We noted a significant relationship between PCSK9 levels and PWV changes at T1 and T2. In conclusion, PCSK9 levels were associated with baseline PWV values in HeFH subjects; moreover, we found that PCSK9 level variations seemed to be correlated with PWV changes on LLT. A longer observation time and wider sample size are needed to assess the potential role of PCSK9 plasma levels on the vascular function and remodelling, and to clarify the effects of PCSK9-i in these pathways. MDPI 2022-04-09 /pmc/articles/PMC9033040/ /pubmed/35454151 http://dx.doi.org/10.3390/biom12040562 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Toscano, Arianna
Cinquegrani, Maria
Scuruchi, Michele
Di Pino, Antonino
Piro, Salvatore
Ferrara, Viviana
Morace, Carmela
Lo Gullo, Alberto
Imbalzano, Egidio
Purrello, Francesco
Squadrito, Giovanni
Scicali, Roberto
Mandraffino, Giuseppe
PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
title PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
title_full PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
title_fullStr PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
title_full_unstemmed PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
title_short PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
title_sort pcsk9 plasma levels are associated with mechanical vascular impairment in familial hypercholesterolemia subjects without a history of atherosclerotic cardiovascular disease: results of six-month add-on pcsk9 inhibitor therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033040/
https://www.ncbi.nlm.nih.gov/pubmed/35454151
http://dx.doi.org/10.3390/biom12040562
work_keys_str_mv AT toscanoarianna pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT cinquegranimaria pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT scuruchimichele pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT dipinoantonino pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT pirosalvatore pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT ferraraviviana pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT moracecarmela pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT logulloalberto pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT imbalzanoegidio pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT purrellofrancesco pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT squadritogiovanni pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT scicaliroberto pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy
AT mandraffinogiuseppe pcsk9plasmalevelsareassociatedwithmechanicalvascularimpairmentinfamilialhypercholesterolemiasubjectswithoutahistoryofatheroscleroticcardiovasculardiseaseresultsofsixmonthaddonpcsk9inhibitortherapy